Considering the strong synergistic effects of WEE1 kinase inhibitors with other downstream target inhibitors in KRAS-mutated lung cancer [26–31], we hypothesize that WEE1 inhibitors can also exert synergistic effects with KRAS G12C targeted inhibitors. This evidence concerns the gene KRAS and lung carcinoma.